108 results about "Norovirus" patented technology

The invention provides an mRNA (messenger ribonucleic acid) vaccine and application of the mRNA vaccine in preparation of a medicine for treating tumors. The vaccine consists of ionizable lipid, cholesterol, phospholipid, a PEG (Polyethylene Glycol) derivative and mRNA (Messenger Ribonucleic Acid) containing a gene sequence for coding norovirus S protein fusion tumor antigen or a gene sequence for coding tumor antigen fusion ferritin. According to the mRNA vaccine designed by the invention, the antigen expression quantity is increased, a nanocrystallization antigen structure is formed to promote antigen processing and presentation, strong anti-tumor cell immune response is stimulated, and a tumor local microenvironment is effectively remodeled, so that a remarkable tumor inhibition effect is achieved.

The invention discloses an anti-norovirus VP1 protein antibody and application thereof, discloses an anti-VP1 protein antibody, a fragment or a fusion protein thereof, comprising a heavy chain variable region and a light chain variable region, and also provides a separated polynucleotide, a carrier, a host cell and a pharmaceutical composition comprising the anti-VP1 protein antibody, the fragment or the fusion protein thereof, the invention also discloses a method for preparing the anti-VP1 protein antibody, the fragment or the fusion protein thereof, a method for detecting the existence or the amount of the VP1 protein or the norovirus in a sample, and an application of the anti-VP1 protein antibody, the fragment or the fusion protein in a corresponding medicament for treating, preventing or relieving diseases or symptoms responding to VP1 protein inhibition, and a method for preparing the anti-VP1 protein antibody, the fragment or the fusion protein and the method for detecting the existence or the amount of the VP1 protein or the norovirus in a sample. The invention also relates to application in production of a product for detecting the VP1 protein or the norovirus.

The invention is applicable to the technical field of virus detection, and provides a norovirus detection kit based on a photo-thermal isothermal amplification technology and a detection method, the norovirus detection kit comprises a nucleic acid amplification chamber, the nucleic acid amplification chamber is provided with reaction micropores for nucleic acid amplification; an RT-PRA system, a CRISPR-cas12a system, a blank control and a positive control are placed in the reaction micropore, the RT-PRA system comprises RT-PRA solutions R1-R5, and the CRISPR-cas12a system comprises CRISPR-Cas12a solutions C1-C3; and the photo-thermal film covers the nucleic acid amplification chamber and is used for converting sunlight into heat energy and radiating the heat energy to liquid in the reaction micropores so as to provide reaction temperature for nucleic acid amplification. According to the invention, the portable, rapid and accurate detection of norovirus infection can be realized, the detection cost can be effectively reduced, the application scene is wide, workers can be helped to deduce the virus transmission path, and key support is provided for investigation and analysis of norovirus epidemic situations.

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

The invention relates to the technical field of microbiological detection, and particularly discloses a primer probe combination for detecting six food-borne pathogens and application of the primer probe combination. The detection primer probe combination for the six food-borne pathogens comprises six pairs of specific primer pairs and six probes, the nucleotide sequences of the specific primer pairs are respectively shown as SEQ ID NO.1, SEQ ID NO.4, SEQ ID NO.8, SEQ ID NO.1, SEQ ID NO.13, SEQ ID NO.16, SEQ ID NO.19, SEQ ID NO.22, SEQ ID NO.26, SEQ ID NO.29, SEQ ID NO.32 and SEQ ID NO.35, and the nucleotide sequences of the probes are respectively shown as SEQ ID NO.37-SEQ ID NO.42; the six food-borne pathogens comprise listeria monocytogenes, salmonella, vibrio parahaemolyticus, norovirus, escherichia coli O157: H7 and staphylococcus aureus. According to the present invention, the pathogens of six common food-borne diseases can be detected, the detection method has characteristics of high specificity and high sensitivity, and the pathogens do not interfere with each other and do not inhibit each other during the detection so as to achieve good stability.

The invention provides a sexavalent norovirus immune composition. The sexavalent norovirus immune composition comprises virus-like particles or active fragments of GI.1 type norovirus, GII.2 type norovirus, GII.3 type norovirus, GII.4 type norovirus, GII.6 type norovirus and GII.17 type norovirus. The invention also provides a kit comprising the sexavalent norovirus immune composition. The invention also provides application of the sexavalent norovirus immune composition and the kit. The composition or the kit provided by the invention can realize effective immunization aiming at six valence types of GI.1 type, GII.2 type, GII.3 type, GII.4 type, GII.6 type and GII.17 type, and can be effective for a long time after administration.

Disclosed are vaccine compositions, in particular, polyvalent icosahedral compositions for presentation of an mpox antigen. The disclosed compositions may contain an S particle comprising a norovirus (NoV) S domain protein and an mpox antigen, which may be linked via a linker protein domain operatively connected to the norovirus S domain protein and an mpox antigen. Fusion proteins for producing the vaccine compositions, and methods of using the disclosed vaccine composition are also provided.

This invention discloses a method for preparing A, B, and Lewis blood group antigens, wherein the A, B, and Lewis blood group antigens are specifically blood group A. tri Antigen, B tri Antigen, Le a Antigen and Le b Antigen. A one-pot photosensitive method was used to achieve blood group A. tri Antigen, B tri Antigen, Le a Antigen and Le b The method for obtaining large quantities of antigens, as described in this invention, features mild reaction conditions, shortened purification steps, simplicity, high efficiency, environmental friendliness, low cost, and high yield and purity of the target substance. This invention provides a practical and rapid chemical synthesis route for blood type A antigens. tri Antigen, B tri Antigen, Le a Antigen and Le b Antigens provide tools for the development of norovirus vaccines and related antibodies, and therefore have great application prospects.

The invention discloses a large-scale closed public place aerosol virus enrichment monitoring system based on an STM32 main control platform, which combines an air sampler and a microfluidic analysis technology, adopts a temperature and humidity real-time monitoring module, optimizes an air sampling and virus enrichment process, and realizes that an integrated microfluidic analysis unit completes rapid determination of virus concentration. According to the system, virus concentration detection is carried out on an enriched sample by utilizing a double-antibody sandwich enzyme-linked immunoassay technology, and the virus concentration is determined through absorbance measurement. Experiments show that the detection error of the system is lower than 5%, and virus monitoring which is quick in response, convenient to operate and low in cost can be achieved. The system is suitable for monitoring viruses such as influenza, new coronavirus and norovirus in large closed public places, and provides efficient technical support for public health safety.

Disclosed herein are vaccine compositions, in particular, polyvalent icosahedral compositions for antigen presentation. The disclosed compositions may contain an S particle made up of recombinant fusion proteins. The recombinant fusion proteins may include a norovirus (NoV) S domain protein, a linker protein domain operatively connected to the norovirus S domain protein, and an antigen protein domain operatively connected to said linker.

The invention provides a method for predicting the norovirus removal rate of a sewage treatment plant based on machine learning. The method comprises the following steps: acquiring the treatment process and scale data of the current sewage treatment plant; performing result prediction through a pre-trained prediction model based on the processing process and scale data; determining the norovirus removal rate of the current sewage treatment plant and the norovirus concentration in the effluent based on the predicted result; wherein the pre-trained prediction model is obtained by training, verifying and testing a plurality of preset machine learning models through a pre-acquired data set, and the pre-acquired data set comprises treatment processes and scale data of a plurality of known sewage treatment plants, as well as influent norovirus concentration data and effluent norovirus concentration data. The problem that an existing sewage treatment prediction model needs to firstly perform long-time sequence sampling and detection on multiple water quality indexes in inflow water and outflow water of a current sewage treatment plant, and then the model can be established for prediction is solved.

The invention provides a norovirus genome splicing method and device, a medium and a product. The method comprises the following steps: acquiring a norovirus gene database, wherein the norovirus gene database comprises a non-structural protein coding region sub-library and a capsid protein coding region sub-library; obtaining original sequencing data; performing quality control on the original sequencing data to obtain screened sequencing data; comparing and assembling the screened sequencing data with the non-structural protein coding region sub-library, and determining at least one first recombinant coding region; and comparing and assembling the screened sequencing data with the capsid protein coding region sub-library, and determining at least one second recombinant coding region, and splicing the at least one first recombinant coding region and the at least one second recombinant coding region to obtain a recombinant genome sequence. Through the technical scheme disclosed by the invention, efficient and accurate splicing of the recombinant norovirus genome sequence is realized, and the assembly accuracy and efficiency of the recombinant norovirus genome sequence are improved.

The purpose of the present invention is to provide: a human norovirus inactivation agent having an excellent human norovirus inactivation effect; and a sanitary material. The present invention relates to a human norovirus inactivation agent characterized by having a pH of 1 to 6 and comprising (a) ethanol and (b) at least one acid selected from the group consisting of gluconic acid, fumaric acid, lactic acid, malic acid, succinic acid, citric acid, and phosphoric acid.

The invention belongs to the technical field of food-borne pathogenic microorganism detection, and particularly relates to an ortho-position nucleic acid probe for detecting norovirus and application of the ortho-position nucleic acid probe. The invention provides an ortho-position nucleic acid probe for identifying norovirus, the ortho-position nucleic acid probe specifically comprises a polystyrene nanoprobe and a single-chain binding protein coupling probe, and the polystyrene nanoprobe is formed by covalent binding of polystyrene microspheres, lectin and hairpin DNA. The single-chain binding protein coupling probe is formed by combining a norovirus antibody and a nucleic acid molecule through a connecting molecule. The probe is simple in synthesis condition and does not need complex purification steps. According to the present invention, a combined reaction with an activation chain, a hybridization chain reaction reagent and a catalytic self-assembly reagent is performed, and the detection sensitivity is improved through a signal cascade amplification reaction, and can achieve the minimum of 0.15 pg mL <-1 >; and moreover, the gene has excellent specificity, and the delta F'difference between the gene and pathogens of staphylococcus aureus, escherichia coli, rotavirus and astrovirus is extremely remarkable.

Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and / or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

The invention discloses an FUT2 high-expression cell strain as well as application and a method of the FUT2 high-expression cell strain in vaccine quality control, and belongs to the technical field of vaccines. The technical problem to be solved is that a simple and easy-to-operate cell model is lacked in the prior art, and the cell model is used for evaluating the effectiveness of NoV vaccines on the cellular level. According to the key points of the technical scheme, the FUT2 high-expression cell strain is provided, the cell strain is an HEK 293T cell strain (HEK 293T-FUT2-EGFP) with EGFP fluorescence for overexpressing human alpha 1, 2-fucosyltransferase 2 (FUT2), and the cell strain stably expresses H, Lewis b and Lewis y type HBGA antigens; meanwhile, an alternative neutralization experiment of the cell level of the norovirus vaccine based on the cell strain is developed, a basis is provided for interaction research of the norovirus and host cells, and the cell strain has high practical application value.

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.

The invention discloses deoxyribozyme for inhibiting mouse norovirus infection. The deoxyribozyme DP233 provided by the invention can be used for cutting mRNA (messenger ribonucleic acid) of a mouse norovirus VP2 gene and inhibiting norovirus infection. Besides, the deoxyribozyme DP233 disclosed by the invention has relatively good specificity, and can be combined with and cut norovirus VP2mRNA in a targeted manner, so that norovirus infection is effectively inhibited; and the deoxyribozyme DP233 has low toxicity to host cells, and is suitable for being used as a potential tool for antiviral gene therapy. The deoxyribozyme technology provides a brand new means for virus resistance, and has a good application prospect.

Disclosed herein are synthetic VP1 proteins that contain engineered disulfide bonds. In some embodiments, the synthetic VP1 proteins with engineered disulfide bonds self-assemble into non-infectious virus-like particles (VLPs) that are more stable that non-infectious VLPs that resulted from self-assembly of VP1 proteins that lack engineered disulfide bonds.

The present invention relates to a peptidomimetic compound and a preparation method, a pharmaceutical composition and use thereof. Specifically, the present invention discloses a peptidomimetic compound represented by general formula (I), or its racemate, cis-trans isomer, enantiomer, diastereomer or mixture thereof, or its metabolite, or its pharmaceutically acceptable salt, solvate or prodrug; the present invention also discloses the use of the compound in inhibiting coronaviruses including SARS-CoV-2, SARS-CoV, MERS-CoV, and other RNA viruses such as EV71, EV68, and norovirus. #imgabs0#

To provide a hydrous fluid composition capable of maintaining anti-norovirus activity even when a lysozyme modified material is stored in water or in a low concentration polar organic solvent.SOLUTION: A hydrous fluid composition contains a lysozyme modified product and / or a salt thereof, and a cationic surfactant, the hydrous fluid composition having a fluorescence intensity, as defined in (A) below, of 5000 or more. (A) Fluorescence intensity: obtained by diluting with a phosphate buffer (pH 7.0) so that the concentration of the lysozyme modified product and / or the salt is 0.05% by mass in terms of solid content and the concentration of lysozyme modified product and / or the salt and the concentration of a phosphate is 0.2 M. The liquid obtained by adding 25 μL of a methanol solution of 8 mM 1,8-anilinonaphthalenesulfonic acid to 5 mL of the diluted solution was allowed to react at room temperature for 30 minutes, and the excitation wavelength was 390 nm (excitation bandwidth 10 nm) and the fluorescence intensity measured under the condition of excitation wavelength 390 nm (excitation bandwidth 10 nm) and fluorescence wavelength 470 nm (fluorescence bandwidth 10 nm).SELECTED DRAWING: None

A peptide that specifically binds to norovirus, which is useful for detection and infection control of norovirus is provided. A norovirus-binding peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 327.

The invention relates to the technical field of molecular biology, in particular to a primer group, a kit and a method for detecting GII type norovirus. The invention discloses a primer group for detecting a GII type norovirus. The primer group can be used for LAMP (Loop-Mediated Isothermal Amplification) to quickly amplify the sequence of the GII type norovirus. The invention further discloses a method for rapidly detecting the GII type norovirus, according to the method, a certain amount of dUTP and UDG are added into an LAMP amplification system, the probability of false positive can be reduced, meanwhile, gene amplification is conducted through LAMP, the method has the advantages of being rapid and convenient to use, an amplified product is tested through LFD, and a result can be visually displayed on LFD. The method has the advantages of rapidness, high efficiency and certain anti-pollution capability.

A pre-saturated wipe product is disclosed that is well suited for destroying non-enveloped viruses, including norovirus. The wipe composition includes a first antimicrobial agent blended with a second agent, such as a preservative. The wipe product can destroy and kill non-enveloped viruses completely in a relatively short contact time, even at very low concentrations in the wipe composition.

The invention relates to a multiplex fluorescent genotyping detection primer probe group and a kit aiming at a norovirus epidemic strain, and belongs to the technical field of biology. The primer probe group comprises a primer pair and a probe which are used for detecting the GII.17 type, the GII.3 type and the GII.4 type of the noroviruses; wherein the nucleotide sequences of the primer pair and the probe for detecting the GII.17 type are as shown in SEQ ID NO: 1-3; the nucleotide sequences of the primer pair and the probe for detecting the GII.3 type are as shown in SEQ ID NO: 4-6; the nucleotide sequences of the primer pair and the probe for detecting the GII.4 type are as shown in SEQ ID NO: 7-9. The method has the following technical effects: 1, the detection time is short, the operation is simple and convenient, and the total detection time is about 1.5 hours; 2, the sensitivity is high; 3, the detection limit is low, and the method can be applied to environmental specimen detection.

The application discloses a CRISPR-Cas12h1 system-based norovirus visual on-site detection kit and belongs to the field of virus detection. A label-free visual nucleic acid detection kit based on CRISPR-Cas12h1 is developed, and large experimental instruments and professional operators are not needed. The detection result can be read within 30 minutes under room temperature conditions, and the detection result is visible to the naked eye and can be directly read. A nucleic acid detection kit for norovirus is developed by using a CRISPR-Cas12h1 nucleic acid detection platform. The detection sensitivity and specificity of the nucleic acid detection kit are not lower than those of existing detection kits. Meanwhile, the nucleic acid detection kit has the advantages of not needing large instruments and professional equipment, short detection time, and visible results to the naked eye, which are not possessed by current detection methods.

The present invention discloses an anti-norovirus VP1 protein antibody and its applications. The present invention discloses an anti-VP1 protein antibody, its fragment or fusion protein, which comprises a heavy chain variable region and a light chain variable region. The present invention also provides an isolated polynucleotide, a vector, a host cell and a pharmaceutical composition comprising the aforementioned anti-VP1 protein antibody, its fragment or fusion protein. The present invention also discloses a method for preparing the aforementioned anti-VP1 protein antibody, its fragment or fusion protein, a method for detecting the presence or amount of VP1 protein or norovirus in a sample. The present invention also provides the use in a corresponding medicament for treating, preventing or alleviating a disease or disorder responsive to the inhibition of VP1 protein, and the use in the production of a product for detecting VP1 protein or norovirus.

The present invention discloses a soluble single-chain antibody that broadly recognizes human norovirus and a preparation method thereof, relating to the field of biotechnology. The amino acid sequence of the soluble single-chain antibody is shown in SEQ ID No. 3; the preparation method comprises: obtaining the nucleotide sequence of the soluble single-chain antibody J5D that broadly recognizes hNoV; constructing a recombinant prokaryotic expression plasmid pMAL-c5X-J5D; and prokaryotic expression and purification of J5D. The amino acid sequence of the recombinant prokaryotic expression plasmid pMAL-c5X-J5D is shown in SEQ ID No. 4. The soluble single-chain antibody J5D is used in a reagent that broadly recognizes human norovirus. The present invention provides a simple and easy method for preparing a scFv that broadly recognizes different genotypes of hNoV. An scFv that broadly recognizes different genotypes of hNoV was successfully prepared, with strong specificity, high stability, and simple operation.

To provide a method for accurately and quantitatively detecting human norovirus having activity.SOLUTION: A method for detecting a human norovirus according to the present invention is a method for detecting a human norovirus having an activity present in a test object, the method including the steps of preparing a magnetic bead-bound body in which an anti-human norovirus IgY antibody is bound to a surface of a magnetic bead, mixing the test object containing the human norovirus with the magnetic bead-bound body, collecting the magnetic bead-bound body, separating an RNA virus genome of the human norovirus bound to the magnetic bead-bound body, synthesizing cDNA from the separated RNA virus genome and amplifying the cDNA, and determining that the human norovirus having the activity is present when an amount of an amplification product obtained in the amplifying step is higher than a reference value.SELECTED DRAWING: Figure 1

The application provides a kit for detecting GI-type norovirus, a detection method and application, and belongs to the technical field of immunological detection. The kit for detecting GI-type norovirus comprises an enzyme label plate coated with GI-type norovirus VP1 protein, HRP-labeled secondary antibody, positive control, negative control, sample diluent, cleaning solution, color developing solution and termination solution. The kit is specific and high in sensitivity, and can accurately detect whether GI-type norovirus is contained in a sample. The application can greatly improve the detection efficiency of front-line inspection and quarantine personnel at ports, and maximally prevent the occurrence of imported infectious diseases.